Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics to $165 from $158 and keeps a Hold rating on the shares as part of a broader research note on Healthcare Services. The firm is introducing 2026 estimates and 2025 quarterly estimates across several verticals while also adjusting its model estimates on select names, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.